Eli Estey

Appointments and Affiliations

University of Washington
School of Medicine
Hematology
Professor, Appointed: 2008
 
Fred Hutchinson Cancer Research Center
Clinical Research Division
Member
 
The University of Texas M.D. Anderson Cancer Center
Division of Medicine
Department of Leukemia Adjunct Professor, Appointed: 2008
 

Mailing Address

Seattle Cancer Care Alliance
G3-200
825 Eastlake Ave E
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 288-7176
Fax: (206) 288-6473
eestey@u.washington.edu

Degrees

M.D., Johns Hopkins University, 1972.
A.B., Yale University, 1968.

Research Interests

Current Clinical Interests
  • Acute myeloid leukemia (AML)

Current Research Interests

  • Clinical trials in AML, particularly those involving new research designs
  • Management of patients with AML

Previous Positions

1993-2007: Professor of Medicine and Internist, Department of Leukemia, University of Texas M.D. Anderson Cancer Center.
1984-1993: Associate Professor of Medicine and Internist, Department of Hematology, University of Texas M.D. Anderson Cancer Center.
1983-1984: Cancer Expert, Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute.
1980-1983: Assistant Professor of Medicine and Internist, Department of Developmental Therapeutics, University of Texas MD Anderson Hospital.

Additional Experience

1978-1980: Fellow, Department of Developmental Therapeutics, University of Texas M.D. Anderson Hospital
1976-1978: Chief Resident in Neurology, New York University-Bellevue Medical Center
1975-1976: Resident in Neurology, New York University-Bellevue Medical Center
1974-1975: Senior Resident in Medicine, New York University-Bellevue Medical Center
1973-1974: Junior Resident in Medicine, New York University-Bellevue Medical Center
1972-1973: Intern in Medicine, New York University-Bellevue Medical Center,

Memberships

Member, American Society of Hematology
Member, American Society of Clinical Oncology Board
Member, Board, MDS Foundation
Southwest Oncology Group

Honors and Awards

Best Doctors in America, 2009-2010
America’s Top Doctors for Cancer
Hubert L. and Olive Stringer Professorship in Medical Oncology, University of Texas M.D. Anderson Cancer Center
Faculty Achievement Award in Clinical Research, University of Texas M.D. Anderson Cancer Center, 1997 (award given to one faculty member annually)
Leukemia Research Foundation Award, 1986
Special Fellow, Leukemia Society of America, 1983

Board Certification and Eligibility

American Board of Internal Medicine; 1975
Subspecialty - Medical Oncology; 1982

Current License(s) to Practice

Washington State
Texas; Texas State License; F5200
Texas; Drug Enforcement Administration DEA); BE2827890
Texas; Texas Controlled Substances (DPS); F0046491

Editorial Positions

Blood, 2011-present
Associate Editor, Haematologica, 2008-present
Journal of Clinical Oncology, 2001–2005
Leukemia, 2000–2005

Funding

  • Principal Investigator; National Institute of Health – IP01 CA108631-01A1, “New Approaches to Treatment and Biology of MDS”; 2005-2010; $ 9.5 million ($ 1.9 million annually)
  • Project Leader - P01 CA55164 (Therapy of AML, M. Andreeff,PI) $133,647 annually 6/1/92-6/30/05; I was PI 2005-2008(until I moved to U. Washington) and am now am co-PI
  • Principal Investigator; National Cancer Institute – IR21 CA10341-01, “Elimination of Chemotherapy in newly-diagnosed APL”; 2004-2006.
  • Principal Investigator; Eli Lilly, Pilot/Phase I and Pharmacodynamic Study of Carboplatin + Gemcitabine in Relapsed/Refractory AML or High-Risk Myelodysplasia; 1998-2000; $36,000
  • Principal Investigator; M. D. Anderson Cancer Center; Multidisciplinary Research Program; Therapy and characterization of myelodysplastic syndrome; 1999-2003; $250,000
  • Co-Investigator; Biochemical Strategies to Increase Leukemia Response; Varsha Gandhi (PI); 9/1998-8/2003; $809,173
  • Harold Tull Trust Fund for Clinical & Translational Research; 5/1997-present; $445,713.92
  • Project Director; U01 CA 62461-05; Project 3- Leukemia Phase I Trials; James Abbruzzese (PI); 2/1998-1/1999; $48,704
  • Principal Investigator; Wyeth Ayerst Research; A Study of the Efficacy and Safety of CMA-676 as a Single Agent Treatment of Patients with AML in First Relapse; 12/1997-12/1998; $42,150
  • Principal Investigator; Aronex Pharmaceuticals, Inc.; Phase II Study of Monotherapeutic Treatment Using Atragen (Liposomal-Tretinoin) in Patinets with Newly-Diagnosed Acute Promyelocytic Leukemia (APL); 4/1997-4/1999; $93,625.00
  • Faculty Achievement Awards; 9/1997- ; $35,000
  • Estate of Marie I. Morgan Fund for Kidney Cancer Research; 6/1997- ; $29,000
  • Project Director; PO-1 CA55164 years 1-4; Project 1-Chemotherapy; Michael Andreeff (PI); 4/1/1997-5/1/2001; $333,148
  • Principal Investigator; Fujisawa USA Inc. Ambisome for Treatment of Fungal Infections; 4/1/1997-12/30/1997; $100,000
  • Principal Investigator; Immunex Co., Prophylactic Transfusion of White Blood From Donors Given GM-CSF to Newly-Diagnosed AML or MDS Patients at High Dose of Fatal Infection; 9/1/1996-9/1/1999; $216,000
  • Principal Investigator; Pharmacia Co. Randomized study of Fludarabine +Ara -C + Idarubicin + G-CSF + ATRA in Poor Prognosis Newly-Diagnosed AML or MDS; 4/1/1996-4/1/1997; $28,000
  • Principal Investigator; Eli Lilly and Co. Phase I/II study of Gemcitabine in Relapsed AML; 9/15/1995-9/15/1997; $24,000
  • Principal Investigator; Cell Therapeutics Inc. Phase II Randomized Single-Blind Placebo Controlled Pilot Study of Lisofylline in AML Patients Undergoing Induction Chemotherapy; 5/1/1995-5/1/1997; $206,000
  • Principal Investigator; Argus Pharmaceuticals Inc.; Phase II Multicenter Study of AR623 in Relapsed APL; 11/1/1994-11/1/1997; $73,000
  • Principal Investigator; Adria Laboratories; Phase II Studies of Idarubicin + Ara-C + G-CSF + Fludarabine in Newly-Diagnosed AML (DM93-048 and 93-049); 04/1/1994-04/1/1996; $40,000
  • Principal Investigator; Argus Pharmaceuticals, Inc.; Phase I Study of AR-623 (Liposomal Tretinoin) in Patients with Hematologic Malignancies; 05/1/1993-05/1/1995; $68,500
  • Project Director; PO1-CA55164, years 1-4, Therapy of AML; Project 1, "Clinical Trials of Growth Regulatory Molecules and Chemotherapy to Reduce Leukemia Burden"; Albert Deisseroth (PI); 5/26/1992-6/30/1996; $159,940
  • Principal Investigator; University of Texas MD Anderson Cancer Center Physicians Referral Service (PRS) Clinical Research Grant; Bayesian Statistical Methods for Design and Analysis of Clinical Trials in AML; 11/1/1992-11/1/1994; $36,000
  • Co-Investigator; RO1-CA32839, years 9-13; Cellular Pharmacology in Cancer Chemotherapy; William Plunkett (PI); 6/1/1991-7/31/1996; $685,478
  • Co-Investigator; RO1-CA57629, years 1-3; Biochemical Strategies to Increase Leukemia Response; Varsha Gandhi (PI); 9/1/1992-8/31/1995; $273,633
  • Co-Investigator; University of Texas MD Anderson Cancer Center Physicians Referral Service (PRS) Clinical Research Grant; Minimal Residual Disease in Acute Myelogenous Leukemia; K-S. Chang (PI); 11/1/1992-11/1/1994; $65,000
  • Co-Investigator; RO3-CA53311, years 1-2; Biochemical Modulation to Increase Leukemia Response; Varsha Gandhi (PI); 9/1/1990-8/31/1992; $74,479
  • Principal Investigator; Cancer Fighters of Houston Inc.; IL-2 as Post-Remission Therapy of AML; 6/1/1991-6/1/1992; $30,000
  • Principal Investigator; An Open-Label, Phase II (Proof of Concept) Trial of PKC412 Monotherapy in Patients with Acute Myeloid Leukemia (AML) and Patients with High Risk Myelodysplastic Syndrome MDS) DM02-089; 3/22/2002–11/30/2003; $13,461.
  • Principal Investigator; Pilot Phase I and Pharmacodynamic Study of Gemcitabine, ara-C, Fludarabine in Refractory/Relapsed AML; DMP98-023; 9/16/1998-12/31/2001; $28,800
  • Principal Investigator; Phase II Monotherapeutic Treatment Using Atragen (Liposomal Tretinoin) in Patients with Newly Diagnosed Acute Promyelocytic Leukemia; DM97-153; 4/1/1997-12/31/2001; $93,625
  • Principal Investigator; Therapy of Better Prognosis AML/MDS with Chemotherapy and Atragen (Liposomal Tretinoin); DM99-202; 12/1/1999-12/31/2001; $70,000

Recent Publications

2017
2016
Estey E.  2016.  Acute Myeloid Leukemia - Many Diseases, Many Treatments.. The New England journal of medicine. 375(21):2094-2095.
2015
Gao W, Estey E.  2015.  Moving toward targeted therapies in acute myeloid leukemia.. Clinical advances in hematology & oncology : H&O. 13(11):748-54. Abstract
Bar M, Tong W, Othus M, Loeb KR, Estey EH.  2015.  Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):546-51. Abstract

Coming Soon: New Profiles System!

In preparation for the launch of our new profiles system, we are freezing updates to these profiles. If you have any questions, please email library@fredhutch.org.

Researcher Profiles

 

Related Websites

 

Scientific Divisions